Julie Dubois

Also affiliated with Institute for Work and Health, Centre universitaire de médecine générale et santé publique, Lausanne

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study”.

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Journal of Clinical Oncology(2020)10.1200/jco.20.00948

N/A

4.9DataRank · unranked

223 citations

Jenny Wu, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario +23 more

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood(2024)10.1182/blood.2023022564

N/A

0.505DataRank · unranked

28 citations

Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Othman Al-Sawaf +19 more